Lakeside Diversifies into China Pharma, Bolstering Logistics Core

TL;DR

**LSH's pivot into Chinese pharma is a bold, high-growth gamble that could pay off big, but watch for execution risks in a new market.**

AI Summary

Lakeside Holding Ltd (LSH) reported a strategic shift in its fiscal year ended June 30, 2025, by entering the pharmaceutical distribution market in China through the acquisition of Hupan Pharmaceutical in late 2024. This new segment, headquartered in Wuhan, China, focuses on brand promotion and healthcare technology support, with infusion fluids being major products. Concurrently, LSH continued its core business as a U.S.-based integrated cross-border supply chain solution provider, specializing in ocean and air freight solutions for the Asian market. The company fulfilled over 14,000 cross-border supply chain orders during the year, contributing to an aggregate assessed value of $1.0 billion since inception. Its logistics operations leverage 142,484 square feet of warehousing space across Illinois and Texas, handling up to 3,000 cubic meters of freight daily. The company also facilitated customs clearance for freight valued over $54.0 million. While specific revenue and net income figures are not provided in this excerpt, the expansion into pharmaceuticals represents a significant diversification strategy.

Why It Matters

Lakeside Holding's strategic entry into the Chinese pharmaceutical distribution market through Hupan Pharmaceutical is a significant move, diversifying its revenue streams beyond its established cross-border logistics business. This could offer investors new growth avenues in a high-demand sector, potentially stabilizing earnings against fluctuations in global trade. For employees, it opens opportunities in a new industry vertical, while customers in both logistics and pharmaceuticals benefit from expanded service offerings. This diversification also positions LSH to compete with larger, more established logistics firms by offering specialized services and tapping into the lucrative healthcare supply chain, particularly in the Asian market.

Risk Assessment

Risk Level: medium — The company is expanding into a new, highly regulated market (pharmaceutical distribution in Mainland China) which introduces significant operational and regulatory risks. While the core logistics business is established, the success of Hupan Pharmaceutical, acquired in late 2024, is unproven and subject to different competitive dynamics and supply chain complexities. The filing mentions 'changes in the competitive environment' and 'laws and regulations of the jurisdictions in which we operate' as general risks, which are amplified by this new venture.

Analyst Insight

Investors should closely monitor Lakeside Holding's upcoming financial reports for specific revenue and profitability metrics from the Hupan Pharmaceutical segment. Evaluate the integration success and market penetration in China, as this new venture represents a significant growth driver but also introduces new risks. Consider the potential for increased volatility given the dual-market exposure.

Financial Highlights

debt To Equity

X.X

revenue

$X

operating Margin

X%

total Assets

$X

total Debt

$X

net Income

$X

eps

$X

gross Margin

X%

cash Position

$X

revenue Growth

+X%

Revenue Breakdown

Key Numbers

• $1.0B — Aggregate assessed value of cross-border supply chain orders (Fulfilled since inception as of June 30, 2025, demonstrating significant operational scale.)
• 14,000 — Cross-border supply chain orders completed (During the fiscal year ended June 30, 2025, indicating active and growing logistics operations.)
• $54.0M — Aggregate assessed value of customs-cleared freight (As of June 30, 2025, highlighting a key service offering and its scale.)
• 142,484 sq ft — Aggregate warehousing and distribution center area (Across Illinois and Texas, providing substantial physical infrastructure for logistics.)
• 3,000 cubic meters — Daily floor load capacity (Of freight at regional warehousing and distribution centers, showcasing operational throughput.)
• 100% — Equity interest acquired (In Hupan Pharmaceutical in late 2024, marking a full strategic entry into a new market.)
• 6.5M units — Pharmaceutical products sourced (From 7 suppliers and delivered to 47 customers during the year ended June 30, 2025, indicating initial scale in the new segment.)
• 17,427,559 — Shares of common stock outstanding (As of October 10, 2025, providing insight into the company's share structure.)
• 48 — U.S. states served (For cross-border order deliveries, demonstrating broad domestic reach.)
• 200+ — Domestic ground transportation carriers collaborated with (As of June 30, 2025, indicating an extensive logistics network.)

Key Players & Entities

• Lakeside Holding Limited (company) — registrant and U.S.-based integrated cross-border supply chain solution provider
• Hupan Pharmaceutical (Hubei) Co., Ltd. (company) — wholly owned subsidiary and new pharmaceutical distribution business in China
• Sichuan Hupan Jincheng Enterprise Management Co., Ltd. (company) — wholly owned subsidiary of Lakeside and parent of Hupan Pharmaceutical
• The Nasdaq Stock Market LLC (regulator) — exchange where LSH Common Stock is registered
• American Bear Logistics Corp. (company) — referred to as ABL, likely a key operational entity or platform
• $20,250,000 (dollar_amount) — aggregate market value of common equity held by non-affiliates as of December 30, 2024
• $54.0 million (dollar_amount) — aggregate assessed value of cross-border freight assisted with customs clearance as of June 30, 2025
• $1.0 billion (dollar_amount) — aggregate assessed value of cross-border supply chain solution orders fulfilled since inception as of June 30, 2025
• 14,000 (dollar_amount) — number of cross-border supply chain orders completed during the year ended June 30, 2025
• 142,484 square feet (dollar_amount) — aggregate gross feet area of regional warehousing and distribution centers

FAQ

Risk Factors

• Jurisdictional Law Compliance [medium — regulatory]: LSH operates in multiple jurisdictions, facing potential challenges from differing or conflicting laws and regulations, or their application and interpretation, which could lead to non-compliance issues.
• Intellectual Property Protection [medium — operational]: The company faces risks related to the failure to protect its intellectual property rights or allegations of infringing on the intellectual property rights of others, which could result in legal disputes and financial liabilities.
• Personnel Retention and Development [medium — operational]: The failure to retain, attract, and develop experienced and qualified personnel is a significant risk that could impact the company's ability to execute its strategies and maintain operational efficiency.
• Disaster and Pandemic Impact [high — operational]: LSH is exposed to risks from natural or man-made disasters, including health pandemics like COVID-19 and the impacts of climate change, which can disrupt operations and supply chains.
• Cybersecurity and Data Breach [high — operational]: System or network disruptions or breaches could lead to operational interruptions, improper disclosure of confidential data, and damage to the company's reputation and financial standing.
• Technology Development and Implementation [medium — operational]: The ability to develop, implement, update, and enhance new technology is critical for LSH's operations and competitive positioning. Failure in this area could hinder growth and efficiency.
• Third-Party Performance [medium — operational]: The company relies on third parties for aspects of its business operations and client services. Any failure or underperformance by these third parties could negatively impact LSH's service delivery and reputation.
• Business Growth and New Ventures [medium — financial]: The costs and risks associated with continuing to grow and develop the business, including entering new lines of business or products like pharmaceuticals, present inherent uncertainties and potential financial strain.

Industry Context

Lakeside Holding Ltd operates in two distinct but increasingly interconnected industries: global logistics and pharmaceutical distribution. The logistics sector is highly competitive, characterized by evolving e-commerce demands, global trade dynamics, and the need for efficient, technology-driven supply chains. The pharmaceutical distribution market, particularly in China, is growing rapidly but is also subject to stringent regulations and requires specialized handling and compliance expertise.

Regulatory Implications

LSH faces significant regulatory scrutiny in both its logistics and pharmaceutical segments. Compliance with international trade laws, customs regulations, and pharmaceutical distribution laws in China are critical. The company must navigate potentially differing legal frameworks across jurisdictions and ensure robust data privacy and cybersecurity measures to avoid penalties and reputational damage.

What Investors Should Do

1. Monitor integration of Hupan Pharmaceutical
2. Assess cross-border logistics performance
3. Evaluate risk factor mitigation

Key Dates

• 2024-XX-XX: Acquisition of Hupan Pharmaceutical — Marks a significant strategic diversification into the Chinese pharmaceutical distribution market.
• 2025-06-30: Fiscal Year End — Reporting period for the strategic shift and operational performance, including the initial impact of the pharmaceutical segment.
• 2025-10-10: Shares Outstanding Date — Provides a snapshot of the company's equity structure as of a specific date.

Glossary

Cross-border supply chain solution provider

A company that offers integrated services for moving goods between countries, including freight, customs, warehousing, and domestic transport. (This is LSH's core business, highlighting their expertise in international logistics.)

Hupan Pharmaceutical

A pharmaceutical distribution and supply chain service provider in Wuhan, China, acquired by LSH. (Represents LSH's new, diversified segment focused on the Chinese pharmaceutical market.)

Infusion fluids

Medical fluids administered intravenously, a major product category for LSH's new pharmaceutical segment. (Indicates a specific product focus within the new pharmaceutical distribution business.)

Freight consolidation and forwarding

Services that combine smaller shipments into larger ones for transport and manage the logistics of moving goods on behalf of shippers. (A key component of LSH's cross-border logistics offerings.)

Customs clearance

The process of obtaining permission from government authorities to ship goods into or out of a country. (A critical service provided by LSH, facilitating international trade for their clients.)

Aggregate assessed value

The total value of goods or services as determined for a specific purpose, such as customs duties or order fulfillment. (Used to quantify the scale of LSH's customs clearance and order fulfillment operations.)

Year-Over-Year Comparison

The fiscal year ended June 30, 2025, marks a significant strategic pivot for Lakeside Holding Ltd with the acquisition of Hupan Pharmaceutical, introducing a new pharmaceutical distribution segment in China. While the core U.S.-based cross-border supply chain solutions business continues to operate, evidenced by over 14,000 orders and $1.0 billion in aggregate assessed value since inception, the company's risk profile has expanded due to entry into a new, highly regulated market. Specific year-over-year comparisons for revenue, net income, and margins are not detailed in this excerpt, but the diversification suggests a shift in the company's operational focus and potential for new growth avenues alongside existing logistics services.

Key Financial Figures

• $0.0001 — h Registered Common Stock, par value US$0.0001 per share LSH The Nasdaq Stock Market L
• $ — er to the legal currency of China; "US$," "U.S. dollars," "$," and "dollars" re
• $54.0 million — of an aggregate assessed value of over $54.0 million. Leveraging our strong cross-border su
• $1.0 b — eight of an aggregate assessed value of $1.0 billion, among which, 14,000 orders were

Filing Documents

• ea0260152-10k_lakeside.htm (10-K) — 1459KB
• ea026015201ex23-1_lakeside.htm (EX-23.1) — 3KB
• ea026015201ex31-1_lakeside.htm (EX-31.1) — 10KB
• ea026015201ex31-2_lakeside.htm (EX-31.2) — 10KB
• ea026015201ex32-1_lakeside.htm (EX-32.1) — 4KB
• image_001.jpg (GRAPHIC) — 21KB
• ex23-1_001.jpg (GRAPHIC) — 18KB
• ex23-1_002.jpg (GRAPHIC) — 11KB
• 0001213900-25-098720.txt ( ) — 9663KB
• lsh-20250630.xsd (EX-101.SCH) — 88KB
• lsh-20250630_cal.xml (EX-101.CAL) — 93KB
• lsh-20250630_def.xml (EX-101.DEF) — 472KB
• lsh-20250630_lab.xml (EX-101.LAB) — 808KB
• lsh-20250630_pre.xml (EX-101.PRE) — 501KB
• ea0260152-10k_lakeside_htm.xml (XML) — 1119KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 9 Item 1B. Unresolved Staff Comments 9 Item 1C. Cybersecurity 9 Item 2.

Properties

Properties 9 Item 3.

Legal Proceedings

Legal Proceedings 9 Item 4. Mine Safety Disclosures 9 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 10 Item 6. Reserved 10 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 11 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 24 Item 9A.

Controls and Procedures

Controls and Procedures 24 Item 9B. Other Information 24 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 24 PART III Item 10. Directors, Executive Officers and Corporate Governance 25 Item 11.

Executive Compensation

Executive Compensation 29 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 32 Item 13. Certain Relationships and Related Transactions, and Director Independence 33 Item 14. Principal Accounting Fees and Services 34 PART IV Item 15. Exhibits, Financial Statement Schedules 35 Item 16. Form 10-K Summary 36

Signatures

Signatures 37 i EXPLANATORY NOTE As used in this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, references to: "Lakeside," "the Company," "we," "us," and "our" refer to Lakeside Holding Limited together with its consolidated subsidiaries; "ABL" refer to American Bear Logistics Corp. "Sichuan Hupan" refer to Sichuan Hupan Jincheng Enterprise Management Co., Ltd., a PRC limited liability company in China and a wholly owned subsidiary of Lakeside; "Hupan Pharmaceutical" refer to Hupan Pharmaceutical (Hubei) Co., Ltd., a PRC limited liability company in China and a wholly owned subsidiary of Sichuan Hupan; "RMB" and "Renminbi" refer to the legal currency of China; "US$," "U.S. dollars," "$," and "dollars" refer to the legal currency of the United States. ii CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report, including statements regarding guidance, our future results of operations or financial condition, our future stock repurchase programs or stock dividends, business strategy and plans, user growth and engagement, product initiatives, objectives of management for future operations, and advertiser and partner offerings, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expres

financial statements;

financial statements; the impact of, and potential challenges in complying with, laws and regulations of the jurisdictions in which we operate, particularly given the possibility of differing or conflicting laws and regulations, or the application or interpretation thereof, across such jurisdictions; failure to protect intellectual property rights or allegations that we have infringed on the intellectual property rights of others; the failure to retain, attract and develop experienced and qualified personnel; the effects of natural or man-made disasters, including the effects of the COVID-19 and other health pandemics and the impacts of climate change; any system or network disruption or breach resulting in operational interruption or improper disclosure of confidential, personal, or proprietary data, and resulting liabilities or damage to our reputation; our ability to develop, implement, update and enhance new technology; the actions taken by third parties that perform aspects of our business operations and client services; and our ability to continue, and the costs and risks associated with, growing and developing our business, and entering into new lines of business or products. iii Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K

Business

Item 1. Business. Overview We are a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. We primarily provide customized cross-border ocean freight solutions and airfreight solutions in the U.S. that specifically cater to our customers' requirements and needs in transporting goods into the U.S. We offer a wide variety of integrated services under our cross-border ocean freight solutions and cross-border airfreight solutions, including (i) cross-border freight consolidation and forwarding services, (ii) customs clearance services, (iii) warehousing and distribution services and (iv) U.S. domestic ground transportation services. For the year ended June 30, 2025, we also operate a new business segment through Hupan Pharmaceutical, a comprehensive pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China with verticals in brand promotion and healthcare technology support. We have partnered with some pharmaceutical manufacturers to supply infusion fluids, which are our major pharmaceutical products sold and distributed during this quarter. Founded in Chicago, Illinois in 2018, we are an Asian American-owned business rooted in the U.S. with in-depth understanding of both the U.S. and Asian international trading and logistics service markets. Our customers are typically Asia- and U.S.-based logistics service companies serving large e-commerce platforms, social commerce platforms and manufacturers to sell and transport consumer and industrial goods made in Asia into the U.S. We have established an extensive collaboration network of service providers, including global freight carriers for our cross-border freight consolidation and forwarding services as well as domestic ground transportation carriers for our U.S. domestic transportation services. We operate three massive and hyper-busy regional warehousing and distribution centers in the U.S., in

View Full Filing

View this 10-K filing on SEC EDGAR